 | |
| Company type | Public |
|---|---|
| KRX:068270 | |
| Industry | Biopharmaceutical |
| Founded | 2002; 23 years ago (2002) |
| Founder | Seo Jung-jin |
| Headquarters | Yeonsu-gu,Incheon,South Korea |
Area served | Worldwide |
Key people | Seo Jung-jin, Chairman Kee Woo-sung, CEO |
| Products | Remsima™,Truxima™,Herzuma™, Biosimilar Drug |
| Revenue |  ₩828,917 million (2017)[1] |
| ₩517,385 million (2017)[1] | |
| ₩403,181 million (2017)[1] | |
| Total assets | ₩3,255,319 million (2017)[1] |
| Total equity | ₩2,522,076 million (2017)[1] |
| Owner | Celltrion Holdings Co., Ltd. (23.03%) Ion Investments B.V. (9.54%) National Pension Service (6.07%) |
| Subsidiaries | Celltrion Entertainment |
| Website | www |
Celltrion, Inc. (Korean: 주식회사 셀트리온) is a biopharmaceutical company headquartered inIncheon,South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion.[2] Celltrion's founder,Seo Jung-jin, is the richest person in South Korea.[3] Seo Jung-jin, its founder was awarded the 2021 EY World Entrepreneur Of The Year.[4]
In 1999, Nexol, Inc. (now Celltrion Healthcare Co., Ltd.) was founded as a global business management consulting firm. In 2002, Celltrion, Inc. was founded as a biopharmaceutical company.[5]
In 2008, Nexol and Celltrion established a global distribution agreement.[6]
In 2009, distribution channels were established in America, Oceania, Europe (Hospira) and Nexol, Inc. renamed as Celltrion Healthcare Co., Ltd.
In 2010, distribution channels were established in Japan (Nippon Kayaku), Commonwealth of Independent States (CIS), Eastern Europe, and theMiddle East (Egis).
In 2013, distribution channels were added in Europe (Mundipharma, Biogaran, and Kern).[7][8]
In September 30, 2024, Celltrion completed the establishment of its oversees corporation in Vietnam.[9]22 Oct. 2024. Celltrion secured a 100.4 billion won ($72.8 million) deal for contract development and manufacturing (CDMO) with TEVA Pharmaceuticals International for the migraine treatment Ajovy.[10]
In November 2024, Celltrion acquired iQone Healthcare Switzerland, a pharmaceutical company for around 30 billion won ($21 million). This move will help its expansion in Europe.[11]
In August 2025, Celltrion was announced to have made a bid of $504.3 million forEli Lilly's BB50 Branchburg, NJ site.
The company's products are manufactured at mammalian cell culture facilities designed and built to comply with the United StatesFDA’s cGMP,[12] and theEuropean Medicines Agency’s GMP standards.[13]
Remsima (infliximab) is abiosimilarmonoclonal antibody againsttumor necrosis factor alpha (TNF-α), approved by theEuropean Medicines Agency (EMA) for treatment of:
In 2012 Remsima was approved by the Republic of Korea's Ministry of Food and Drug Safety (MFDS), previously known as Korea Food and Drug Administration and in 2013 it became the world's first[15]biosimilarmonoclonal antibody (mAb) approved by the EMA.[14]
Herzuma is abiosimilartrastuzumab approved by the MFDS for treatment of early and advanced (metastatic)HER2+breast cancer as well as advanced (metastatic)stomach cancer. Herzuma is a HER2+ breast cancer therapy designed to treat aggressive HER positivemetastatic andadjuvant breast cancer, as well as HER2 positiveadenocarcinoma of the stomach that has spread (metastatic or advancedgastric cancer).[16][17][18]
Truxima (previously known as CT-P10) is the first biosimilar of the referencemonoclonal antibodyrituximab that targets CD20 molecule primarily found on the surface ofB-cells. Its target indications are rheumatoid arthritis,non-Hodgkin lymphoma andchronic lymphocytic leukemia.[19][20] It was approved by the EMA in February 2017.[21]
| Company name | Shareholding ratio |
|---|---|
| Celltrion Holdings | 20.05% |
| Korea National Pension Service | 7.26% |
| Celltrion Skincure | 2.11% |
| As of Sep 2023. | |
| Companies | |||||||
|---|---|---|---|---|---|---|---|
| Government and regulatory bodies | |||||||
| Industry and professional bodies |
| ||||||
| Other | |||||||
